Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

American Journal of Epidemiology

Volumn 158, Issue 9, 2003, Pages 915-920

  Ray, Wayne A ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bias (epidemiology); Confounding factors (epidemiology); Epidemiologic research design; Hormone replacement therapy; Pharmacoepidemiology; Research design

Indexed keywords

DESIGN; EPIDEMIOLOGY;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFECT; DRUG USE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; METHODOLOGY; PHARMACOEPIDEMIOLOGY; PREVALENCE; REVIEW;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); EPIDEMIOLOGIC RESEARCH DESIGN; HORMONE REPLACEMENT THERAPY; HUMANS; PHARMACOEPIDEMIOLOGY;

EID: 0142157169     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwg231     Document Type: Review

References (46)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
2. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
3. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
5. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000;342:1907-9.
6. Petitti DB. Hormone replacement therapy and heart disease prevention. JAMA 1998;280:650-2.
7. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
8. Cauley JA, Seeley DG, Browner WS, et al. Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. Arch Intern Med 1997;157:2181-7.
9. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:366-8.
10. Humphrey LL, Chan BKS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
11. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observation studies. Lancet 2001;357:455-62.
12. Feinstein AR. Clinical biostatistics. XI. Sources of 'chronology bias' in cohort statistics. Clin Pharmacol Ther 1971;12:864-79.
13. Feinstein AR. Sources of 'chronology bias'. Clinical biostatistics. St Louis, MO: The C V Mosby Company, 1977:89-104.
14. Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Boston, MA: Little, Brown & Company, 1991.
15. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-50.
16. Guess HA. Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time. J Clin Epidemiol 1989;42:1179-84.
17. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-72.
18. Ray WA, Thapa P, Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000;48:682-5.
19. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal antiinflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-45.
20. Burkhart GA, Brown NJ, Griffin MR, et al. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. Pharmacoepidemiol Drug Safety 1996;5:149-54.
21. Suissa S, Spitzer WO, Rainville B, et al. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000;15:817-21.
22. Yola M, Lucien A. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47:731-7.
23. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999;159:161-6.
24. Ray WA. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol 1992;12:386-96.
25. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-41.
26. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990;336:542-5.
27. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1993;270:742-4.
28. Pizzo PA, Robichaud KJ, Edwards BK, et al. Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. J Pediatr 1983;102:125-33.
29. Rothman KJ, Greenland S, eds. Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven, 1998.
30. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339:875-82.
31. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in post-menopausal women. Epidemiology 2000;11:382-7.
32. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
33. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? Ann Intern Med 1994;121:289-300.
34. Wacholder S, McLaughlin JK, Silverman DT, et al. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992;135:1019-28.
35. Wacholder S, Silverman DT, McLaughlin JK, et al. Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol 1992;135:1029-41.
36. Wacholder S, Silverman DT, McLaughlin JK, et al. Selection of controls in case-control studies. III. Design options. Am J Epidemiol 1992;135:1042-50.
37. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989;129:837-49.
38. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev 1990:87-107.
39. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000;355:2185-8.
40. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262:3303-7.
41. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24.
42. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
43. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002;8:276-9.
44. Morris JN, Hawes C, Fries BE, et al. Designing the national resident assessment instrument for nursing homes. Gerontologist 1990;30:293-307.
45. Becker SL, Raffanti SR, Hansen NI, et al. Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. J Acquir Immune Defic Syndr 2001;26:72-81.
46. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-7.